The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I

Patrick Schöffski(KU Leuven), Willy Peetermans(KU Leuven), Ben Vancleynenbreugel(Universitair Ziekenhuis Leuven), Philippe Moerman(KU Leuven), Christophe M. Deroose(KU Leuven), Olivier Gheysens(Cliniques Universitaires Saint-Luc), Nele Lips(KU Leuven), Koen Slabbaert(Universitair Ziekenhuis Leuven)

BMC Medical Imaging

May 29, 2014

10.1186/1471-2342-14-19

Cited by 3

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

|The Lancet|2012|2.1k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

|The Lancet Oncology|2014|1.2k

Risk factors for community-acquired pneumonia in adults in Europe: a literature review

|Thorax|2013|861

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

|The Lancet|2016|766